Clinical bottom line
Pediatric sudden-onset sensorineural hearing loss (SSNHL) with suspected autoimmune etiology remains a challenging diagnosis with evolving management strategies. Current evidence suggests autoimmune mechanisms may underlie a subset of pediatric SSNHL cases, warranting consideration of immunomodulatory therapies alongside standard corticosteroids. However, diagnostic criteria are not standardized, and confirmatory testing is limited. Early recognition and tailored treatment may improve auditory outcomes, but further research is needed to clarify optimal diagnostic pathways and therapeutic regimens.
What the evidence shows
Sudden sensorineural hearing loss in children is rare but clinically significant, with autoimmune causes representing a putative subset (Hanson et al., 2026). García Berrocal et al. (2024) review the autoimmune hypothesis, highlighting that immune-mediated inner ear damage may result from circulating autoantibodies or immune complex deposition, leading to cochlear inflammation and dysfunction. This autoimmune subset may present with bilateral involvement, fluctuating hearing loss, or association with systemic autoimmune diseases.
Diagnostic evaluation remains complex. Rodríguez Izquierdo et al. (2024) emphasize the role of comprehensive audiologic assessment, laboratory autoimmune panels, and imaging—particularly MRI to exclude retrocochlear pathology (Herrera et al., 2024). However, no single test reliably confirms autoimmune SSNHL, and diagnosis is often presumptive based on clinical features and exclusion of other causes.
Therapeutically, systemic corticosteroids remain first-line treatment for pediatric SSNHL, with some evidence supporting adjunctive immunosuppressants or biologics in refractory or recurrent cases suspected to be autoimmune (Hanson et al., 2026). Goswami et al. (2026) present a case linking latent autoimmune diabetes in adults with SSNHL, suggesting systemic autoimmune dysregulation may contribute to hearing loss pathogenesis and supporting immunomodulation as a rational approach.
Practice patterns vary widely. Luu et al. (2023) report unresolved diagnostic uncertainty and heterogeneous management strategies in pediatric SSNHL, underscoring the need for consensus guidelines and standardized protocols integrating autoimmune considerations.
Caveats and uncertainty
The autoimmune etiology of pediatric SSNHL remains a hypothesis-generating area with limited high-quality evidence. Most data derive from case series, expert opinion, and extrapolation from adult studies. Biomarkers for inner ear autoimmunity lack sensitivity and specificity, complicating diagnosis (García Berrocal et al., 2024). The natural history of autoimmune SSNHL in children is not well characterized, and the benefit-risk profile of immunosuppressive therapies beyond corticosteroids is unclear.
MRI is critical to exclude alternative causes but does not directly confirm autoimmune involvement (Herrera et al., 2024). The heterogeneity of clinical presentations and overlap with viral, vascular, and idiopathic causes further confound diagnosis (Herrera et al., 2024; Hanson et al., 2026).
Therapeutic evidence is largely observational, with no randomized controlled trials specifically addressing autoimmune SSNHL in pediatric populations. Immunosuppressive agents carry potential adverse effects, necessitating cautious patient selection and monitoring.
How this may change practice
Clinicians should maintain a high index of suspicion for autoimmune etiologies in pediatric SSNHL cases with atypical features such as bilateral involvement, fluctuating hearing loss, or systemic autoimmune symptoms. Early multidisciplinary evaluation including rheumatology and immunology consultation may be beneficial.
Standardized diagnostic algorithms incorporating audiologic testing, autoimmune serologies, and MRI can aid in identifying candidates for immunomodulatory therapy. Corticosteroids remain the cornerstone of initial management, but consideration of adjunctive immunosuppressants may be appropriate in refractory or recurrent cases after specialist input.
Ongoing research and consensus development are needed to refine diagnostic criteria, validate biomarkers, and establish evidence-based treatment protocols. Meanwhile, individualized care balancing potential benefits and risks of immunotherapy is warranted.